October 2022—Cofactor Genomics presented initial results from the PREDAPT (Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies) multicenter clinical trial at the Advances in Genome Biology and Technology Precision Health Meeting in September. The company says its data show that Cofactor’s OncoPrism test using predictive immune modeling was nearly twice as accurate as PD-L1 assays in determining who will benefit from immunotherapies such as Keytruda (pembrolizumab).
Read More »Home >> Tag Archives: Cofactor Genomics
RNA-based biomarker panel for cancer, 6/17
June 2017—Cofactor Genomics launched its Pinnacle assay, which looks at gene fusions and gene expression in patient tumor samples to provide physicians with potential treatment targets for cancer patients.
Read More »